EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The immune receptor SLAMF5 regulates myeloid-cell mediated neuroinflammation in multiple sclerosis

Laura Bellassen, Keren David, Bar Lampert, Avital Sarusi-Portuguez, Michael Tsoory, Jazz Lubliner, Eran Hornstein, Michael Osherov, Ron Milo, Ori Brenner, Shirly Becker-Herman, Idit Shachar iD

PLOS Biology · 2025

DOI: 10.1371/journal.pbio.3003373 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Biology, 2025. Verfasst von Laura Bellassen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. Hauptthemen laut MEDLINE: Signaling Lymphocytic Activation Molecule Family, Encephalomyelitis, Autoimmune, Experimental, Multiple Sclerosis, Myeloid Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Briskin Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic neurological disorder characterized by demyelination of the central nervous system (CNS), leading to a broad spectrum of physical and cognitive impairments. Myeloid cells within the CNS, including microglia and border-associated macrophages, play a central role in the neuroinflammatory processes associated with MS. Activation of these cells contributes to the local inflammatory response and promotes the recruitment of additional immune cells into the CNS. SLAMF5 is a cell surface receptor that functions as a homophilic adhesion molecule, capable of modulating immune cell activity through both activating and inhibitory signals. In this study, we investigated the expression and function of SLAMF5 in CNS-resident and peripheral myeloid cells using the murine model of MS, experimental autoimmune encephalomyelitis (EAE). Our findings demonstrate that both total and brain-specific SLAMF5 deficiency in myeloid cells leads to decreased expression of activation and costimulatory molecules, including MHC class II (MHCII) and CD80. This downregulation is mediated, at least in part, through the transcription factor BHLHE40 and its regulation of CD52, resulting in delayed onset and reduced progression of the disease. Furthermore, pharmacological blockade of SLAMF5 in the brain halted disease progression and reduced the expression of myeloid activation markers. In human studies, SLAMF5 blockade in peripheral monocytes from MS patients and in induced pluripotent stem cell (iPSC)-derived microglia reduced the expression of HLA-DR, CD80, and CD52. Together, these results identify SLAMF5 as a key regulator of myeloid cell activation in neuroinflammation and suggest that it may represent a promising therapeutic target for autoimmune disorders such as MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signaling Lymphocytic Activation Molecule FamilyEncephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisMyeloid CellsNeuroinflammatory DiseasesAnimalsMiceHumansMice, Inbred C57BLMicrogliaFemaleBrainMacrophagesMice, Knockout

Substanzen

Signaling Lymphocytic Activation Molecule Family

Autor:innen und Institutionen

  • Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
  • The Mantoux Bioinformatics Institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel.
  • Behavioral and Physiological Phenotyping Unit, Weizmann Institute of Science, Rehovot, Israel.
  • Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
  • Department of Neurology, Barzilai University Medical Center, Ashkelon, Israel.
  • Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel.

ORCID-Profile: Idit Shachar

Förderung

  • Briskin Foundation

Zitieren

APA

Bellassen, L., David, K., Lampert, B., Sarusi-Portuguez, A., Tsoory, M., Lubliner, J., Hornstein, E., Osherov, M., Milo, R., Brenner, O., Becker-Herman, S., & Shachar, I. (2025). The immune receptor SLAMF5 regulates myeloid-cell mediated neuroinflammation in multiple sclerosis. PLOS Biology. https://doi.org/10.1371/journal.pbio.3003373

Vancouver

Bellassen L, David K, Lampert B, Sarusi-Portuguez A, Tsoory M, Lubliner J, et al. The immune receptor SLAMF5 regulates myeloid-cell mediated neuroinflammation in multiple sclerosis. PLOS Biology. 2025. doi:10.1371/journal.pbio.3003373

BibTeX
@article{Bellassen2025,
  author = {Bellassen, Laura and David, Keren and Lampert, Bar and Sarusi-Portuguez, Avital and Tsoory, Michael and Lubliner, Jazz and Hornstein, Eran and Osherov, Michael and Milo, Ron and Brenner, Ori and Becker-Herman, Shirly and Shachar, Idit},
  title = {The immune receptor SLAMF5 regulates myeloid-cell mediated neuroinflammation in multiple sclerosis},
  journal = {PLOS Biology},
  year = {2025},
  doi = {10.1371/journal.pbio.3003373}
}
Kostenlos starten →